NextCure (NextCure) Price-to-Tangible-Book : 0.34 (As of Apr. 25, 2024)

View and export this data going back to 2019. Start your Free Trial

What is NextCure Price-to-Tangible-Book?

As of today (2024-04-25), NextCure's share price is $1.40. NextCure's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $4.10. Hence, NextCure's Price to Tangible Book Ratio of today is 0.34.

The historical rank and industry rank for NextCure's Price-to-Tangible-Book or its related term are showing as below:

NXTC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.23 Med: 0.71 Max: 4.82
Current: 0.34

During the past 7 years, NextCure's highest Price to Tangible Book Ratio was 4.82. The lowest was 0.23. And the median was 0.71.

NXTC's Price-to-Tangible-Book is ranked better than
96.39% of 1220 companies
in the Biotechnology industry
Industry Median: 2.67 vs NXTC: 0.34

A closely related ratio is called PB Ratio. As of today, NextCure's share price is $1.40. NextCure's Book Value per Sharefor the quarter that ended in Dec. 2023 was $4.10. Hence, NextCure's P/B Ratio of today is 0.34.

NextCure Price-to-Tangible-Book Historical Data

The historical data trend for NextCure's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure Price-to-Tangible-Book Chart

NextCure Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

4.82

1.02

0.71

0.23

0.28

NextCure Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															0.23	0.27	0.36	0.28	0.28

Competitive Comparison of NextCure's Price-to-Tangible-Book

For the Biotechnology subindustry, NextCure's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NextCure's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCure's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where NextCure's Price-to-Tangible-Book falls into.

NextCure Price-to-Tangible-Book Calculation

NextCure's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	1.40	/	4.101
	=	0.34

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

NextCure Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of NextCure's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCure (NextCure) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (NAS:NXTC) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

2US:Germany

Address

9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705

Website

https://www.nextcure.com

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include NC410 a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1, NC762 a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or B7-H4, a protein expressed on multiple tumor types, and NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or AML, blast cells, and leukemic stem cells, or LSCs.

Executives

Anne Elizabeth Borgman	director	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Ellen Feigal	director	C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Kevin G. Shaw	officer: Sr VP, Legal Affairs	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sourav Kundu	officer: Sr VP, Dev. & Mfg.	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Han Myint	officer: Chief Medical Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Timothy Mayer	officer: Chief Operating Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sol Langermann	officer: Chief Scientific Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Steven P. Cobourn	officer: Chief Financial Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Linda Liu	officer: SVP, Research	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Michael Richman	director, officer: President & CEO	2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
John G Houston	director	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Anand Mehra	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Michael Powell	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
James Healy	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025